A Study to Evaluate the Efficacy and Safety of Enlicitide (MK-0616, Oral PCSK9 Inhibitor) Compared With Ezetimibe or Bempedoic Acid or Ezetimibe and Bempedoic Acid in Adults With Hypercholesterolemia (MK-0616-018/CORALreef AddOn)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 301 participants.
Also called NCT06450366
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 301 participants
- Sponsor
- Registry
-
NCT06450366 -
2023-504920-25-00 -
U1111-1290-3888
-
- Other papers using this trial's data
- Oral PCSK9 Inhibitor Enlicitide Versus Oral Nonstatin Therapies: A Phase 3 Randomized Clinical Trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Argentina, Canada, France, Israel, Spain, Taiwan, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT06450366. Randomized; triple masking; primary purpose treatment. Start 2024-07-08 (actual); primary completion 2025-02-14 (actual). Results posted on 2026-03-27.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study to Evaluate the Efficacy and Safety of Enlicitide (MK-0616, Oral PCSK9 Inhibitor) Compared With Ezetimibe or Bempedoic Acid or Ezetimibe and Bempedoic Acid in Adults With Hypercholesterolemia (MK-0616-018/CORALreef AddOn)
- Condition
- Hypercholesterolemia
- Intervention (Drug)
- Enlicitide
- Intervention (Drug)
- Ezetimibe
- Intervention (Drug)
- Bempedoic Acid
- Intervention (Other)
- Placebo for Enlicitide
- Intervention (Other)
- Placebo for Ezetimibe
- Intervention (Other)
- Placebo for Bempedoic Acid
- Lead sponsor
- Merck Sharp & Dohme LLC
Record details
- Record id
cardio:ct-nct06450366- Content hash
d6fc619948e0036942accdcb524a0b7cceb8a59531ae462c7f26c1591e7b7f26